Lastly, the small number of patients, particularly in subgroup analyses, restricted the ability to draw definitive conclusions and highlights the necessity for larger studies with comprehensive clinical data, including stratification by tumor subtype and distinction between BRCA1 and BRCA2 mutation carriers, to validate and extend these findings. The gene discussed is BRCA2; the disease is neoplasm.